Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991

Cancer

Volumn 78, Issue 10, 1996, Pages 2210-2215

  Nakamura, Yukari ^a   Motokura, Toru ^a   Fujita, Akira ^b   Yamashita, Takayuki ^a,c   Ogata, Etsuro ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Showa General Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

chemotherapy; hematologic diseases; hepatitis B virus; liver failure; questionnaires

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CORTICOSTEROID THERAPY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CARRIER STATE; DATA COLLECTION; FEMALE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS, TOXIC; HOSPITALS; HUMANS; JAPAN; MALE; MIDDLE AGED;

EID: 0029861928     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0     Document Type: Article

References (25)

1. Wands JR. Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 1975;2:979.
2. Galbraith RM, Eddleston ALWF, Williams R, Zuckerman AJ, Bagshawe KD. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975:2:528-30.
3. Hanta T, Okita K, Matsuda S, Konishi T, Yasunaga M, Kado Y, et al. A case of fulminant hepatitis developing in a HBsAg carrier after chemotherapy of malignant lymphoma. Nippon Shokakibyo Gakkai Zasshi 1984:81:1089-93.
4. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982:96:447-9.
5. Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogenic bone marrow transplantation. Dig Dis Sci 1988;33:1185-91.
6. Bird GLA, Smith H, Portmann B, Alexander GJM, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med 1989:73:895-902.
7. Pinto PC, Eddie HU, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990:65:878-84.
8. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd D, Chiu EKW. Hepatitis B infection in patients with lymphoma. Hematol Oncol 1990; 8:261-70.
9. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-8.
10. Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991;21:360-5.
11. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992:37:1253-9.
12. Tanaka J, Yoshizawa H. Epidemiology of hepatitis virus B and C. Igaku No Ayumi 1994; 171:959-64.
13. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious disease. 4th edition. New York: Churchill Livingstone Inc, 1995: 1406-39.
14. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B, Gastroenterology 1981;81: 987-91.
15. Statistics Bureau, Management and Coordination Agency. Japan statistical yearbook. 43rd edition. Tokyo: Japan Statistical Association, 1993:668.
16. Tur-Kaspa R, Burk RD, Shaul Y, Shafrits DA. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci USA 1986;83:1627-31.
17. Sagnelli E, Manzillo G, Maio G, Pasquale G, Felaco FM, Filippini P, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAgpositive chronic active hepatitis, Lancet 1980:2:395-7.
18. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991:324:1699-704.
19. Ehata T, Omata M, Chuang WL, Yokosuka O, Ito Y, Hosoda K, et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993:91:1206-13.
20. Liang TJ, Hasegawa K, Munoz SJ, Shapiro CN, Yoffe B, McMahon BJ, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. J Clin Invest 1994;93:550-5.
21. Lee JH, Bisceglie AMDI, Baker BL, Zeldis JB. The development of a mutation in the precore region of the hepatitis B virus in a chronically infected individual. Gastroenterology 1994;106:243-7.
22. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yonomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241-8.
23. Tsujii T, Fukui H, Yoshikawa M. Etiology of chronic hepatitis. Nippon Naika Gakkai Zasshi 1994;83:181-5.
24. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogenic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant 1991:8:417-20.
25. Vento S, Cainelli F, Mirandola F, Cosco L, Perri GD, Solbiati M, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996:347:92-3.